These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 32877161)

  • 21. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
    Zhu MMT; Dancsok AR; Nielsen TO
    Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cinnamaldehyde-based poly(thioacetal): A ROS-awakened self-amplifying degradable polymer for enhanced cancer immunotherapy.
    Tu Y; Xiao X; Dong Y; Li J; Liu Y; Zong Q; Yuan Y
    Biomaterials; 2022 Oct; 289():121795. PubMed ID: 36108580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
    Chen Q; Chen M; Liu Z
    Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase.
    Han X; Cheng K; Xu Y; Wang Y; Min H; Zhang Y; Zhao X; Zhao R; Anderson GJ; Ren L; Nie G; Li Y
    J Am Chem Soc; 2020 Feb; 142(5):2490-2496. PubMed ID: 31944687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomaterial-assisted photoimmunotherapy for cancer.
    Chen M; Chen Q
    Biomater Sci; 2020 Nov; 8(21):5846-5858. PubMed ID: 33016276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Near-Infrared Photoactivatable Immunomodulatory Nanoparticles for Combinational Immunotherapy of Cancer.
    Yu N; Ding M; Li J
    Front Chem; 2021; 9():701427. PubMed ID: 34109160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy.
    Xu W; Liu W; Yang J; Lu J; Zhang H; Ye D
    Immunol Rev; 2024 Jan; 321(1):181-198. PubMed ID: 37403660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in small molecule based cancer immunotherapy.
    Cheng B; Yuan WE; Su J; Liu Y; Chen J
    Eur J Med Chem; 2018 Sep; 157():582-598. PubMed ID: 30125720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering nanoparticle strategies for effective cancer immunotherapy.
    Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
    Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy.
    Yu B; Zhang W; Kwak K; Choi H; Kim DH
    ACS Appl Mater Interfaces; 2020 Dec; 12(49):54415-54425. PubMed ID: 33237729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of antitumor immunotherapy using mitochondria-targeted cancer cell membrane-biomimetic MOF-mediated sonodynamic therapy and checkpoint blockade immunotherapy.
    Luo J; Wang X; Shi Z; Zeng Y; He L; Cao J; Sun Y; Zhang T; Huang P
    J Nanobiotechnology; 2022 May; 20(1):228. PubMed ID: 35568916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.